This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?

Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles

This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond

This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.

The NephJC Summer Book Club returns! We turn to fiction this time, 'The Covenant of Water', from Abraham Verghese.

This week, we will discuss an intriguing hypothesis for many nephrologists: can amino acids prevent acute kidney injury?

Is living kidney donation safe or does it bring hypertension and potential kidney badness on the horizon? This week we will be focusing on an encouraging JAMA article, hoping to be close to a more definitive answer

This week, we will discuss the RaDaR study. Does rare mean kidney failure occurs rarely? What are rare diseases? Do we see them in children more than adults? All this and more!

This week, we will maybe not expect the worse, while discussing the COMPASS post hoc analysis. Are PPIs so bad for the kidneys?